Trevi Q2 net loss narrows to $8.1M; Haduvio achieves all endpoints in Phase 2b/3 prurigo nodularis trial

Trevi Therapeutics, Inc.

2022-Q2 EPS reported -$0.34

Q2 2022 net loss of $8.1M ($9.8M in Q2 2021); cash and securities $78.9M.
Phase 2b/3 PRISM trial met primary endpoint (25% vs 14% WI-NRS 4-point reduction, p=0.0157) and all key secondary endpoints with statistical significance.
Completed $55M private placement in April 2022 to fund clinical development of Haduvio.
Topline data from Phase 2 CANAL chronic cough in IPF trial expected Q3 2022; FDA meeting scheduled for this quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.